Hostname: page-component-cd9895bd7-7cvxr Total loading time: 0 Render date: 2024-12-25T05:09:55.223Z Has data issue: false hasContentIssue false

Controlled Trial of the Treatment of 36 Stutterers

Published online by Cambridge University Press:  29 January 2018

P. G. Wells
Affiliation:
Royal Southern Hospital, Liverpool; Young People's Unit, Victoria Road, Macclesfield
M. T. Malcolm
Affiliation:
Royal Southern Hospital, Liverpool; West Cheshire Hospital, Chester

Extract

Stutter, tic and the Gilles de la Tourette syndrome have many features in common. Haloperidol has been found of value in the treatment of the last-named syndrome (1) and also of tic (2). Our study was intended to evaluate its use, combined with orphenadrine, in stutterers. We used it both with and without speech therapy, as shown in Table I. The trial was controlled, and double blind. Our 36 patients, aged 15 to 60, were of both sexes and neither psychotic nor subnormal. They were not on other therapy. They were randomly divided by an independent third party equally into the following groups, and treated as indicated.

Type
Research Article
Copyright
Copyright © Royal College of Psychiatrists, 1971 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

1. Challas, G., Chapel, J. L., and Jenkins, R. L. (1968). ‘Tourette's disease: control of symptoms and its clinical course.’ Int. J. Neuropsychiatry, 4, 96108.Google Scholar
2. Connell, P. H., Corbett, J. A., Horne, J. J., and Mathews, A. M. (1967). ‘Drug treatment of adolescent tiqueurs.’ Brit. J. Psychiat., 113, 375–81.Google ScholarPubMed
3. Gattuso, R., and Leocata, A. (1962). ‘Haloperidol in the treatment of stuttering.’ Clinica Otorinolaringoiatrica, 14, number 5 1962.Google Scholar
Submit a response

eLetters

No eLetters have been published for this article.